With evidence pointing to a capacity for reciprocal D-type cyclin substitution in MM under trametinib treatment, the fundamental function of cyclin D2 in compensating for diminished cyclin D1 in early trametinib resistance was examined. This evidence concerns the gene CCND2 and Miyoshi myopathy.